



**FOR IMMEDIATE RELEASE...**

## **QRONO TAILORS STRATEGIC PLAN THROUGH NIH PROGRAM**

*Business Accelerator Helps Qrono Maximize Platform Value*

PITTSBURGH (PRWEB) June 4, 2018 – Qrono Inc., a biotechnology company pioneering a new class of locally-administered tumor immunotherapies, recently completed the National Institutes of Health (NIH) 2017-2018 Commercialization Accelerator Program (CAP).

The NIH CAP is a 9-month program that facilitates strategic planning and customer discovery to focus participating companies and their product pipelines for the pursuit of external investment and industry partnerships. The program, organized by Larta Inc., is exclusively for HHS/NIH SBIR/STTR Phase II awardees and limited to 80 grantees each year. As a participant this year, Qrono received expert help a team of regulatory and industry veterans. Sam Rothstein, CEO at Qrono Inc. worked closely with this team to refine Qrono’s product-milestone focus for stronger industry resonance and improved strategic development.

“The CAP program provided a wealth of feedback from regulatory experts and industry-experienced entrepreneurs.” said Dr. Rothstein. “I’d like to personally thank our principal advisor Vivek Mittel, the rest of the program mentors, and the team at Larta for their help advancing our business strategy.”

“I enjoyed working with Sam on Qrono’s commercialization approach.” said Vivek. “We achieved a clear understanding of Qrono’s unique therapies and tailored a strategy for maximizing their value.”

Qrono’s unique immunoengineering approach to cancer therapy repurposes known medications with advanced polymer formulations to change signaling within a treated tumor and its immune cells. This approach brings new specificity to target pathways impacting multiple cancers and is expected to have broad application. Qrono is actively exploring ways to enhance cancer-specific immune responses and abrogate tumor immunosuppression with its IND-stage pharmaceutical pipeline.

###

**About Qrono:** Qrono is developing a unique pipeline of locally administered immunotherapies for solid tumor cancers. Qrono’s products reach key targets within tumors and induce changes in the immune microenvironment to overcome known treatment limitations. Its lead product QR206 is in ongoing Investigational New Drug enabling studies for head and neck cancer, where few patients respond to standard therapies.

**Qrono media contact: Sam Rothstein, CEO Phone: +1-412-213-8448**  
**Email: srothstein@qrono.com**